AI-generated analysis. Always verify with the original filing.
Ensysce Biosciences reported a net loss of $10.2 million for the full year 2025, driven by increased R&D spending for its lead drug candidates PF614 and PF614-MPAR, while highlighting clinical and regulatory progress including Phase 3 trial initiation and FDA engagement.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor w
Financial Statements and Exhibits.** (d) Exhibits. | Exhibit Number | | Description | |---|---|---| | | | | | 99.1 | | Press Release, dated March 30, 2026 | | |
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $10.2M | |
| Net Loss Per Share | $3.98 | |
| Research and Development Expenses | $10.4M | |
| General and Administrative Expenses | $4.9M | |
| Federal Grants | $5.1M |